Bio News

Novo Nordisk has signed a research collaboration agreement worth up to $1.4 billion (approximately 1.88 trillion won) with Denmark-based Orbis Medicines to develop oral macrocyclic peptides.
Orbis Medicines will identify macrocyclic candidates targeting cardiometabolic diseases in exchange for upfront payments, milestone payments and sales royalties.
Novo Nordisk aims to use macrocyclic technology to overcome the digestive absorption limitations that mean the highest dose of oral Wegovy is 20 times the highest injectable dose.

BIOBOOK TEAM
biobookmedia@biobook.co.krEuropean CHMP Recommends Approval of AstraZeneca’s Blood Pressure Drug Baxpendi
Novo Seeks U.S. and European Approval for Sickle Cell Drug Etavopivat
Rezolute Meets Primary Endpoint in Phase 3 Trial for Tumor Hyperinsulinism; FDA Meeting Ahead
Five Brain Disease Startups Raise $450 Million in a Few Weeks
American Cancer Society Revises Prostate Cancer Screening Guidelines for First Time in 16 Years
Shin Dong-kook Raises Stake in Hanmi Science to 30.18% With Over-the-Counter Purchase of 1.38 Million Shares